Mariner
BDTX icon

Mariner’s Black Diamond Therapeutics BDTX Stock Holding History

Mariner’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$48.5K Buy
+25,718
New +$50.4K ﹤0.01% 3356
2025
Q2 		– Sell
-11,911
Closed -$18.5K – 3492
2025
Q1 		$18.5K Buy
+11,911
New +$25K ﹤0.01% 3383
2022
Q4 		– Sell
-10,734
Closed -$18K – 2746
2022
Q3 		$18K Buy
+10,734
New +$33.1K ﹤0.01% 2385

Other funds holding BDTX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Mariner's BDTX Position: Q3 2026 in Review

Mariner opened a new position in Black Diamond Therapeutics (BDTX) in Q3 2026: 25,718 shares worth $48.5K. The stake represents ﹤0.01% of the portfolio and ranks #3356 among its holdings. This is a return to the name: Mariner previously reported a position in BDTX as recently as Q1 2025.

Mariner first reported a position in BDTX in Q3 2022 and has held it in 3 quarters since. 77 funds tracked by Wall St. Rank hold BDTX as of Q3 2026.

  • Mariner held 25,718 shares of Black Diamond Therapeutics worth $48.5K as of Q3 2026.
  • Black Diamond Therapeutics was a new Mariner position in Q3 2026.
  • Black Diamond Therapeutics made up ﹤0.01% of Mariner's portfolio in Q3 2026, its #3356 holding.
  • Mariner first reported a position in Black Diamond Therapeutics in Q3 2022 and has held it in 3 quarters since.
  • 77 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2026.

Based on Mariner's 13F filing for Q3 2026, filed 12 Nov 2026.